{
  "docId": "019de076-48c2-7315-bf77-72d2721572a4",
  "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91",
  "documentTitle": "Immatics | Investor Presentation Deck | 75 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 54,
  "pageCount": 75,
  "prevPage": 53,
  "nextPage": 55,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/54",
  "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4",
  "deckJsonHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4.json",
  "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-54",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Phase 1a: Dose Escalation to Phase 1b: Dose Expansion",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a44bdc3-51c7-41a3-81e1-bc42ffaa73b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "MTD: maximum tolerated dose, RP2D: recommended phase 2 dose; MABEL: minimum anticipated biological effect level; BLRM: Bayesian logistic regression model; 1 Pharmacokinetics data assessed throughout the trial might provide an opportunity to optimize scheduling to a less frequent regimen. 2 Conducted in collaboration with BMS",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc72b9a6-d920-41fa-892a-b50fea4ef6fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Determine MTD and/or RP2D; Safety and tolerability; Initial anti-tumor activity; Pharmacokinetics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "000ea93e-0c78-4e48-84ff-de9fb386946f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.36,
        "y": 0.7
      },
      "kind": "list",
      "text": "Focus on specific indications planned",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1dd505-10f8-4565-8729-1bb08139fe21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.06,
        "y": 0.7
      },
      "kind": "list",
      "text": "Weekly i.v. infusions; Dose escalation decisions based on cohorts of 1-6 patients in adaptive design (BLRM model)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac32f3ed-cc88-4344-bd8d-a670f402a4ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbb56a79-7816-463a-8c97-8df65cdb8518",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Hypothesis-Driven Structure",
      "slug": "hypothesis-driven-structure",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "5edf58f9-4557-4c63-ad78-eb60fd7f9563",
      "evidence": "The slide outlines a Phase 1 Clinical Trial with a clear hypothesis and structure, including dose escalation and expansion phases.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "bb99d2ea-89c8-473f-8b16-3b04eb27a169",
      "evidence": "The slide outlines the sequential phases of a clinical trial design.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}